Literature DB >> 73014

Effect of piracetam on level of consciousness after neurosurgery.

A E Richardson, F J Bereen.   

Abstract

2-oxopyrollidine acetamide (piracetam) is said to protect the cerebral cortex against hypoxia. Since surgery is believed to aggravate cerebral hypoxia and the consequent neurological dysfunction, patients undergoing surgery for brain tumours or ruptured cerebral aneurysms were studied. A random, non-stratified study of 100 patients showed that a significantly higher percentage of patients receiving piracetam attain or maintain a normal or near-normal level of consciousness postoperatively than those receiving a placebo. No side-effects or interaction of piracetam with other medications were noted.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 73014     DOI: 10.1016/s0140-6736(77)90550-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

1.  Effects of piracetam on brain monoamine metabolism and serum prolactin levels in the rat.

Authors:  H Nybäck; F A Wiesel; P Skett
Journal:  Psychopharmacology (Berl)       Date:  1979-03-28       Impact factor: 4.530

2.  Modulating effect of the nootropic drug, piracetam on stress- and subsequent morphine-induced prolactin secretion in male rats.

Authors:  A Matton; S Engelborghs; F Bollengier; E Finné; L Vanhaeist
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

3.  Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment.

Authors:  G Chouinard; L Annable; A Ross-Chouinard; M Olivier; F Fontaine
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

Review 4.  Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders.

Authors:  M W Vernon; E M Sorkin
Journal:  Drugs Aging       Date:  1991-01       Impact factor: 3.923

5.  Effect of piracetam on the cognitive performance of patients undergoing coronary bypass surgery: A meta-analysis.

Authors:  Yu Fang; Zhandong Qiu; Wentao Hu; Jia Yang; Xiyan Yi; Liangjiang Huang; Suming Zhang
Journal:  Exp Ther Med       Date:  2013-11-26       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.